New technique developed at Washington University in St. Louis uses blood test
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test.
Hong Chen, a biomedical engineer, and Eric C. Leuthardt, MD, a neurosurgeon, led a team of engineers, physicians and researchers who have developed a groundbreaking, proof-of-concept technique that allows biomarkers from a brain tumor to pass through the tough blood-brain barrier into a patient’s blood using noninvasive focused ultrasound and some tiny bubbles, potentially eliminating the need for a surgical biopsy.
Chen, assistant professor of biomedical engineering in the School of Engineering & Applied Science and of radiation oncology in the School of Medicine, said while researchers have already learned how to get a drug through the blood-brain barrier into the brain via the bloodstream, no one — until now — has found a way to release tumor-specific biomarkers — in this case, messenger RNA (mRNA)— from the brain into the blood.
“I see a clear path for the clinical translation of this technique,” said Chen, an expert in ultrasound technology. “Blood-based liquid biopsies have been used in other cancers, but not in the brain. Our proposed technique may make it possible to perform a blood test for brain cancer patients.”
The blood test would reveal the amount of mRNA in the blood, which gives physicians specific information about the tumor that can help with diagnosis and treatment options.
Results of the study, which blends imaging, mechanobiology, genomics, immunology, bioinformatics, oncology, radiology and neurosurgery, are published in Scientific Reports April 26, 2018.
Chen; Leuthardt, professor of neurological surgery in the School of Medicine; and researchers from the Schools of Engineering & Applied Science and of Medicine, tested their theory in a mouse model using two different types of the deadly glioblastoma brain tumor. They targeted the tumor using focused ultrasound, a technique that uses ultrasonic energy to target tissue deep in the body without incisions or radiation. Similar to a magnifying glass that can focus sunlight to a tiny point, focused ultrasound concentrates ultrasound energy to a tiny point deep into the brain.
Once they had the target — in this case, the brain tumor — researchers then injected microbubbles that travel through the blood similar to red blood cells. When the microbubbles reached the target, they popped, causing tiny ruptures of the blood-brain barrier that allows the biomarkers from the brain tumor to pass through the barrier and release into the bloodstream. A blood sample can determine the biomarkers in the tumor.
This technique could lead to personalized medicine.
“In many ways this has been a holy grail for brain tumor therapy,” Leuthardt said. “Having the ability to monitor the changing molecular events of the tumor in an ongoing way allows us to not only better diagnose a tumor in the brain, but to follow its response to different types of treatment.”
“Once the blood-brain barrier is open, physicians can deliver drugs to the brain tumor,” Chen said. “Physicians can also collect the blood and detect the expression level of biomarkers in the patient. It enables them to perform molecular characterizations of the brain tumor from a blood draw and guide the choice of treatment for individual patients.”
In addition, Gavin Dunn, MD, assistant professor of neurosurgery, a co-author and leader in cancer immunobiology, plans to use the technique with immunotherapy, which offers precision treatment that targets specific biomarkers in the brain.
“This noninvasive focused ultrasound-enabled liquid biopsy technique can be useful for long-term monitoring of brain cancer treatment response, where repeated surgical tissue biopsies may not be feasible,” Chen said. “Meanwhile, variations within tumors pose a significant challenge to cancer biomarker research. Focused ultrasound can precisely target different locations of the tumor, thereby causing biomarkers to be released in a spatially-localized manner and allow us to better understand the spatial variations of the tumor and develop better treatment.”
The team continues to work to refine the process. The future will require integration with advanced genomic sequencing and bioinformatics to enable even more refined diagnostics. These efforts are being led by co-authors Allegra Petti, assistant professor of medicine, and Xiaowei Wang, associate professor of radiation oncology.
“Our ongoing work is to optimize the technique and evaluate its sensitivity and safety,” Chen said.
Learn more: Noninvasive brain tumor biopsy on the horizon
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Safer and more affordable medicine for all? How Pharmacogenomics may level the playing fieldon January 30, 2020 at 10:34 pm
A trained molecular biologist, immunologist, and the former Head of Genomics Science and Biologics at Sanofi, Tocci has worked in drug discovery and pre-clinical development for most of his career, ...
- New resources in precision medicine that every doctor should know abouton January 29, 2020 at 8:12 am
Precision medicine, or personalized medicine as it is sometimes referred to, is a most significant and promising healthcare trend. The National Institutes of Health (NIH) defines precision medicine as ...
- Global Personalized Medicine Market 2020-Laboratory Corporation of America,Quest Diagnostics,Abbott, Becton Dickinson and Coon January 29, 2020 at 2:49 am
Eon Market Research has announced the inclusion of a new market research report to its comprehensive collection of research studies. The 115-page research report, titled "Global Personalized Medicine ...
- Genomic Profiling for Precision Medicine: Interview with David Spetzler, Caris Life Scienceson January 28, 2020 at 1:54 pm
Personalized medicine holds enormous potential in improving patient outcomes, but has been limited by the complexity of contextualizing the molecular or genetic signatures of diseased tissues, such as ...
- Direct-to-consumer genetic tests attempt to capture the zeitgeist of personalized medicineon January 28, 2020 at 3:06 am
We are practicing medicine at the intersection of expectation and limitation ... holistic guidance — and deliver what we as clinicians know is truly personalized care.
- Researchers identify opportunities to advance genomic medicineon January 27, 2020 at 1:52 pm
Cho, MD, Dean of Translational Genetics at the Icahn School of Medicine at Mount Sinai, Director of The Charles Bronfman Institute for Personalized Medicine, and a co-author of the report. "Applying ...
- Addressing Disparities Will Advance Genomics, Precision Medicineon January 27, 2020 at 7:53 am
Cho, MD, Dean of Translational Genetics at the Icahn School of Medicine at Mount Sinai, Director of The Charles Bronfman Institute for Personalized Medicine, and a co-author of the report. “Applying ...
- Artificial Intelligence in Medicine Market Advanced Technology and New Innovations by 2025 – InSilico Medicine, Globavir Bioscienceson January 27, 2020 at 5:02 am
Based on application, the market is categorized into drug discovery & repurposing, clinical research trial, personalized medicine, and others. Based on region, it is analyzed across North America, ...
- Global Personalized Medicine Market revenue to hit USD 3466 Million By 2024on January 24, 2020 at 1:29 am
Zion Market Research added a new report "Global Personalized Medicine Market Set For Rapid Growth To Reach Around USD 3466 Million By 2024" in its database, which provides an expert and in-depth ...
via Bing News